DE60011045T2 - Biolgisch abbaubare glaszusammensetzungen und deren verwendung zur herstellung eines medikaments für strahlungstherapie - Google Patents
Biolgisch abbaubare glaszusammensetzungen und deren verwendung zur herstellung eines medikaments für strahlungstherapie Download PDFInfo
- Publication number
- DE60011045T2 DE60011045T2 DE60011045T DE60011045T DE60011045T2 DE 60011045 T2 DE60011045 T2 DE 60011045T2 DE 60011045 T DE60011045 T DE 60011045T DE 60011045 T DE60011045 T DE 60011045T DE 60011045 T2 DE60011045 T2 DE 60011045T2
- Authority
- DE
- Germany
- Prior art keywords
- mol
- glass
- rare earth
- radioisotope
- radioactive
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000011521 glass Substances 0.000 title claims abstract description 377
- 239000000203 mixture Substances 0.000 title claims abstract description 50
- 238000001959 radiotherapy Methods 0.000 title claims abstract description 32
- 238000004519 manufacturing process Methods 0.000 title claims description 13
- 239000003814 drug Substances 0.000 title claims description 4
- 239000000463 material Substances 0.000 claims abstract description 100
- 230000002285 radioactive effect Effects 0.000 claims abstract description 54
- 239000005374 lithium borate glass Substances 0.000 claims abstract description 49
- 150000001875 compounds Chemical class 0.000 claims abstract description 21
- 210000001124 body fluid Anatomy 0.000 claims abstract description 13
- 239000010839 body fluid Substances 0.000 claims abstract description 13
- 230000000717 retained effect Effects 0.000 claims abstract description 11
- 241000124008 Mammalia Species 0.000 claims abstract description 5
- 239000004005 microsphere Substances 0.000 claims description 126
- 229910052761 rare earth metal Inorganic materials 0.000 claims description 60
- 150000002910 rare earth metals Chemical class 0.000 claims description 45
- 230000005855 radiation Effects 0.000 claims description 39
- 229910018072 Al 2 O 3 Inorganic materials 0.000 claims description 37
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 23
- 229910018068 Li 2 O Inorganic materials 0.000 claims description 22
- 229910004298 SiO 2 Inorganic materials 0.000 claims description 18
- 229910052796 boron Inorganic materials 0.000 claims description 18
- KJZYNXUDTRRSPN-OUBTZVSYSA-N holmium-166 Chemical compound [166Ho] KJZYNXUDTRRSPN-OUBTZVSYSA-N 0.000 claims description 14
- 230000002917 arthritic effect Effects 0.000 claims description 13
- KBQHZAAAGSGFKK-NJFSPNSNSA-N dysprosium-165 Chemical compound [165Dy] KBQHZAAAGSGFKK-NJFSPNSNSA-N 0.000 claims description 13
- -1 rare earth phosphate Chemical class 0.000 claims description 13
- KZUNJOHGWZRPMI-AKLPVKDBSA-N samarium-153 Chemical compound [153Sm] KZUNJOHGWZRPMI-AKLPVKDBSA-N 0.000 claims description 10
- VWQVUPCCIRVNHF-OUBTZVSYSA-N Yttrium-90 Chemical compound [90Y] VWQVUPCCIRVNHF-OUBTZVSYSA-N 0.000 claims description 8
- WUAPFZMCVAUBPE-NJFSPNSNSA-N 188Re Chemical compound [188Re] WUAPFZMCVAUBPE-NJFSPNSNSA-N 0.000 claims description 7
- 229910001404 rare earth metal oxide Inorganic materials 0.000 claims description 7
- WUAPFZMCVAUBPE-IGMARMGPSA-N rhenium-186 Chemical compound [186Re] WUAPFZMCVAUBPE-IGMARMGPSA-N 0.000 claims description 7
- 230000001225 therapeutic effect Effects 0.000 claims description 7
- WHXSMMKQMYFTQS-BJUDXGSMSA-N (6Li)Lithium Chemical compound [6Li] WHXSMMKQMYFTQS-BJUDXGSMSA-N 0.000 claims description 6
- ZOXJGFHDIHLPTG-BJUDXGSMSA-N Boron-10 Chemical compound [10B] ZOXJGFHDIHLPTG-BJUDXGSMSA-N 0.000 claims description 6
- 229910019142 PO4 Inorganic materials 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- RIUWBIIVUYSTCN-UHFFFAOYSA-N trilithium borate Chemical group [Li+].[Li+].[Li+].[O-]B([O-])[O-] RIUWBIIVUYSTCN-UHFFFAOYSA-N 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 8
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 47
- 239000002953 phosphate buffered saline Substances 0.000 description 47
- 239000000243 solution Substances 0.000 description 46
- 238000005260 corrosion Methods 0.000 description 32
- 230000007797 corrosion Effects 0.000 description 32
- 229910052692 Dysprosium Inorganic materials 0.000 description 26
- 239000002245 particle Substances 0.000 description 18
- 230000004580 weight loss Effects 0.000 description 18
- 238000004090 dissolution Methods 0.000 description 17
- KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 210000001503 joint Anatomy 0.000 description 17
- 229910052689 Holmium Inorganic materials 0.000 description 16
- 238000012360 testing method Methods 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 13
- 238000009616 inductively coupled plasma Methods 0.000 description 13
- 210000001258 synovial membrane Anatomy 0.000 description 13
- KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 description 12
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 12
- 239000000126 substance Substances 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000002347 injection Methods 0.000 description 10
- 239000007924 injection Substances 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 210000000629 knee joint Anatomy 0.000 description 9
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 8
- 238000004833 X-ray photoelectron spectroscopy Methods 0.000 description 8
- 229910052782 aluminium Inorganic materials 0.000 description 8
- 238000007654 immersion Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000011324 bead Substances 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 239000000155 melt Substances 0.000 description 6
- 230000008901 benefit Effects 0.000 description 5
- 239000008367 deionised water Substances 0.000 description 5
- 229910021641 deionized water Inorganic materials 0.000 description 5
- 238000005498 polishing Methods 0.000 description 5
- 239000010935 stainless steel Substances 0.000 description 5
- 229910001220 stainless steel Inorganic materials 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000219061 Rheum Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000008240 homogeneous mixture Substances 0.000 description 4
- 210000003127 knee Anatomy 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000011777 magnesium Substances 0.000 description 4
- 239000004570 mortar (masonry) Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 229910052698 phosphorus Inorganic materials 0.000 description 4
- 239000012857 radioactive material Substances 0.000 description 4
- 239000012217 radiopharmaceutical Substances 0.000 description 4
- 229940121896 radiopharmaceutical Drugs 0.000 description 4
- 230000002799 radiopharmaceutical effect Effects 0.000 description 4
- 238000004626 scanning electron microscopy Methods 0.000 description 4
- 210000001179 synovial fluid Anatomy 0.000 description 4
- 229910001260 Pt alloy Inorganic materials 0.000 description 3
- 229910000629 Rh alloy Inorganic materials 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 238000002149 energy-dispersive X-ray emission spectroscopy Methods 0.000 description 3
- 230000005251 gamma ray Effects 0.000 description 3
- 229920001903 high density polyethylene Polymers 0.000 description 3
- 239000004700 high-density polyethylene Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 239000003350 kerosene Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000017074 necrotic cell death Effects 0.000 description 3
- 238000000399 optical microscopy Methods 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 229910052697 platinum Inorganic materials 0.000 description 3
- 229910052573 porcelain Inorganic materials 0.000 description 3
- 239000001294 propane Substances 0.000 description 3
- 239000002331 radioactive microsphere Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000004611 spectroscopical analysis Methods 0.000 description 3
- 239000005341 toughened glass Substances 0.000 description 3
- 208000005422 Foreign-Body reaction Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 2
- 229910052772 Samarium Inorganic materials 0.000 description 2
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 2
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 2
- JFBZPFYRPYOZCQ-UHFFFAOYSA-N [Li].[Al] Chemical compound [Li].[Al] JFBZPFYRPYOZCQ-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 210000001188 articular cartilage Anatomy 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 229910052738 indium Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- WHXSMMKQMYFTQS-IGMARMGPSA-N lithium-7 atom Chemical compound [7Li] WHXSMMKQMYFTQS-IGMARMGPSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000003801 milling Methods 0.000 description 2
- 239000002480 mineral oil Substances 0.000 description 2
- 235000010446 mineral oil Nutrition 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000003439 radiotherapeutic effect Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 239000005361 soda-lime glass Substances 0.000 description 2
- 239000012798 spherical particle Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910052722 tritium Inorganic materials 0.000 description 2
- 238000010865 video microscopy Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010020843 Hyperthermia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 101001094044 Mus musculus Solute carrier family 26 member 6 Proteins 0.000 description 1
- 206010067482 No adverse event Diseases 0.000 description 1
- 241000906034 Orthops Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004111 Potassium silicate Substances 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- PGTAKMRAYVRICI-UHFFFAOYSA-N aluminum lithium borate Chemical compound B([O-])([O-])[O-].[Al+3].[Li+] PGTAKMRAYVRICI-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- HSBONFIDJMNFJD-UHFFFAOYSA-N aluminum potassium borate Chemical compound B([O-])([O-])[O-].[K+].[Al+3] HSBONFIDJMNFJD-UHFFFAOYSA-N 0.000 description 1
- SXQXMCWCWVCFPC-UHFFFAOYSA-N aluminum;potassium;dioxido(oxo)silane Chemical compound [Al+3].[K+].[O-][Si]([O-])=O.[O-][Si]([O-])=O SXQXMCWCWVCFPC-UHFFFAOYSA-N 0.000 description 1
- 239000005347 annealed glass Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- ZOXJGFHDIHLPTG-IGMARMGPSA-N boron-11 atom Chemical compound [11B] ZOXJGFHDIHLPTG-IGMARMGPSA-N 0.000 description 1
- 239000002419 bulk glass Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001739 density measurement Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- UYAHIZSMUZPPFV-NJFSPNSNSA-N erbium-169 Chemical compound [169Er] UYAHIZSMUZPPFV-NJFSPNSNSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006066 glass batch Substances 0.000 description 1
- 238000005816 glass manufacturing process Methods 0.000 description 1
- 239000000156 glass melt Substances 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 230000036031 hyperthermia Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 229910001410 inorganic ion Inorganic materials 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 150000002642 lithium compounds Chemical class 0.000 description 1
- PAZHGORSDKKUPI-UHFFFAOYSA-N lithium metasilicate Chemical compound [Li+].[Li+].[O-][Si]([O-])=O PAZHGORSDKKUPI-UHFFFAOYSA-N 0.000 description 1
- 229910052912 lithium silicate Inorganic materials 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000289 melt material Substances 0.000 description 1
- 238000001000 micrograph Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- NNHHDJVEYQHLHG-UHFFFAOYSA-N potassium silicate Chemical compound [K+].[K+].[O-][Si]([O-])=O NNHHDJVEYQHLHG-UHFFFAOYSA-N 0.000 description 1
- 229910052913 potassium silicate Inorganic materials 0.000 description 1
- 235000019353 potassium silicate Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229910052702 rhenium Inorganic materials 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- KZUNJOHGWZRPMI-NJFSPNSNSA-N samarium-152 Chemical compound [152Sm] KZUNJOHGWZRPMI-NJFSPNSNSA-N 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000005368 silicate glass Substances 0.000 description 1
- 239000003238 silicate melt Substances 0.000 description 1
- 239000012890 simulated body fluid Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000005211 surface analysis Methods 0.000 description 1
- 210000005222 synovial tissue Anatomy 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052727 yttrium Inorganic materials 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/12—Silica-free oxide glass compositions
- C03C3/14—Silica-free oxide glass compositions containing boron
- C03C3/15—Silica-free oxide glass compositions containing boron containing rare earths
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/009—Neutron capture therapy, e.g. using uranium or non-boron material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C3/00—Glass compositions
- C03C3/04—Glass compositions containing silica
- C03C3/062—Glass compositions containing silica with less than 40% silica by weight
- C03C3/064—Glass compositions containing silica with less than 40% silica by weight containing boron
- C03C3/068—Glass compositions containing silica with less than 40% silica by weight containing boron containing rare earths
-
- C—CHEMISTRY; METALLURGY
- C03—GLASS; MINERAL OR SLAG WOOL
- C03C—CHEMICAL COMPOSITION OF GLASSES, GLAZES OR VITREOUS ENAMELS; SURFACE TREATMENT OF GLASS; SURFACE TREATMENT OF FIBRES OR FILAMENTS MADE FROM GLASS, MINERALS OR SLAGS; JOINING GLASS TO GLASS OR OTHER MATERIALS
- C03C2213/00—Glass fibres or filaments
- C03C2213/02—Biodegradable glass fibres
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Geochemistry & Mineralogy (AREA)
- Materials Engineering (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Glass Compositions (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24189299A | 1999-02-01 | 1999-02-01 | |
| PCT/US2000/002388 WO2000044682A1 (en) | 1999-02-01 | 2000-01-31 | Biodegradable glass compositions and methods for radiation therapy |
| US241892 | 2000-10-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60011045D1 DE60011045D1 (de) | 2004-07-01 |
| DE60011045T2 true DE60011045T2 (de) | 2005-05-25 |
Family
ID=22912591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60011045T Expired - Lifetime DE60011045T2 (de) | 1999-02-01 | 2000-01-31 | Biolgisch abbaubare glaszusammensetzungen und deren verwendung zur herstellung eines medikaments für strahlungstherapie |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US6379648B1 (enExample) |
| EP (1) | EP1149057B1 (enExample) |
| JP (1) | JP4397531B2 (enExample) |
| AT (1) | ATE267775T1 (enExample) |
| AU (1) | AU758560B2 (enExample) |
| CA (1) | CA2361573C (enExample) |
| DE (1) | DE60011045T2 (enExample) |
| ES (1) | ES2222892T3 (enExample) |
| WO (1) | WO2000044682A1 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6616591B1 (en) * | 1999-12-08 | 2003-09-09 | Scimed Life Systems, Inc. | Radioactive compositions and methods of use thereof |
| AUPR098300A0 (en) * | 2000-10-25 | 2000-11-16 | Sirtex Medical Limited | Polymer based radionuclide containing microspheres |
| AUPR098200A0 (en) * | 2000-10-25 | 2000-11-16 | Sirtex Medical Limited | Production of low density radionuclide containing microspheres |
| GB0104383D0 (en) * | 2001-02-22 | 2001-04-11 | Psimedica Ltd | Cancer Treatment |
| US6709744B1 (en) * | 2001-08-13 | 2004-03-23 | The Curators Of The University Of Missouri | Bioactive materials |
| GB2383534A (en) * | 2001-12-28 | 2003-07-02 | Psimei Pharmaceuticals Plc | Delivery of neutron capture elements for neutron capture therapy |
| WO2004065949A1 (en) * | 2003-01-21 | 2004-08-05 | X-Ray Flux Pty Ltd | X-ray fluorescence flux composition |
| US20040220135A1 (en) * | 2003-04-30 | 2004-11-04 | Sirtex Medical Limited | Combination therapy for treatment of neoplasia |
| US20040258614A1 (en) * | 2003-06-20 | 2004-12-23 | University Of Maryland, Baltimore | Microparticles for microarterial imaging and radiotherapy |
| US7959900B2 (en) * | 2004-03-05 | 2011-06-14 | Xl Sci-Tech, Inc. | Particulate materials and compositions for radio therapy |
| US9248034B2 (en) * | 2005-08-23 | 2016-02-02 | Advanced Cardiovascular Systems, Inc. | Controlled disintegrating implantable medical devices |
| US20070170396A1 (en) * | 2006-01-26 | 2007-07-26 | Graham Appleby | Photostimulable glass ceramic |
| US20080038190A1 (en) | 2006-08-11 | 2008-02-14 | Simpson Thomas J | Composition apparatus and method for use in imaging |
| US20080119927A1 (en) * | 2006-11-17 | 2008-05-22 | Medtronic Vascular, Inc. | Stent Coating Including Therapeutic Biodegradable Glass, and Method of Making |
| US8353966B2 (en) * | 2009-01-15 | 2013-01-15 | The Curators Of The University Of Missouri | Scaffold for bone and tissue repair in mammals |
| US9456890B2 (en) | 2009-01-15 | 2016-10-04 | The Curators Of The University Of Missouri | Scaffold for bone and tissue repair in mammals |
| US8481066B2 (en) | 2009-07-16 | 2013-07-09 | The Curators Of The University Of Missouri | Scaffold for tissue regeneration in mammals |
| WO2011015958A2 (en) | 2009-08-06 | 2011-02-10 | Koninklijke Philips Electronics N.V. | Oncology therapies employing radioactive seeds |
| US9849200B2 (en) | 2010-09-16 | 2017-12-26 | Mo-Sci Corporation | Strontium phosphate microparticle for radiological imaging and therapy |
| US9119887B2 (en) | 2010-09-16 | 2015-09-01 | Mo-Sci Corporation | Low-density magnesium-aluminum-silicate (MAS) microparticles for radiotherapy and/or radioimaging |
| US8865123B1 (en) | 2010-09-16 | 2014-10-21 | Mo-Sci Corporation | Strontium phosphate microparticle for radiological imaging and therapy |
| EP2457588A1 (en) * | 2010-11-05 | 2012-05-30 | UMC Utrecht Holding B.V. | Microsphere comprising a lanthanide metal complex |
| US9750828B2 (en) * | 2012-03-29 | 2017-09-05 | Basf Corporation | Amorphous carbon supported nanoparticles comprising oxides of lanthanides and method for preparing them |
| EP2968165B1 (en) | 2013-03-13 | 2023-09-13 | Biosphere Medical, Inc. | Compositions and associated methods for radioisotope-binding microparticles |
| CA2937015C (en) | 2014-01-24 | 2022-08-02 | Sirtex Medical Limited | Treatment of neoplasia |
| GB201415005D0 (en) * | 2014-08-22 | 2014-10-08 | Univ Nottingham | Porous and non-pourous bodies |
| US11013836B2 (en) * | 2016-06-16 | 2021-05-25 | The Curators Of The University Of Missouri | Inorganic biodegradable substrates for devices and systems |
| HRP20230566T1 (hr) * | 2017-08-22 | 2023-08-18 | Moebius Medical Ltd. | Liposomalna formulacija za podmazivanje zglobova |
| TWI675669B (zh) * | 2018-03-05 | 2019-11-01 | 白金科技股份有限公司 | 放射微球及其製備方法 |
| NZ774059A (en) * | 2018-09-05 | 2025-11-28 | Ir Scient Inc | Glass composition |
| JP2022547277A (ja) | 2019-09-16 | 2022-11-11 | エービーケー バイオメディカル インコーポレイテッド | 放射性微粒子及び非放射性微粒子の組成物 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3972721A (en) * | 1974-03-01 | 1976-08-03 | Ppg Industries, Inc. | Thermally stable and crush resistant microporous glass catalyst supports and methods of making |
| US5039326A (en) | 1988-01-29 | 1991-08-13 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
| US4889707A (en) | 1988-01-29 | 1989-12-26 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
| US5011797A (en) | 1988-01-29 | 1991-04-30 | The Curators Of The University Of Missouri | Composition and method for radiation synovectomy of arthritic joints |
-
1999
- 1999-02-01 US US09/241,892 patent/US6379648B1/en not_active Expired - Lifetime
-
2000
- 2000-01-31 DE DE60011045T patent/DE60011045T2/de not_active Expired - Lifetime
- 2000-01-31 JP JP2000595944A patent/JP4397531B2/ja not_active Expired - Lifetime
- 2000-01-31 AU AU28647/00A patent/AU758560B2/en not_active Expired
- 2000-01-31 CA CA2361573A patent/CA2361573C/en not_active Expired - Lifetime
- 2000-01-31 EP EP00907088A patent/EP1149057B1/en not_active Expired - Lifetime
- 2000-01-31 WO PCT/US2000/002388 patent/WO2000044682A1/en not_active Ceased
- 2000-01-31 ES ES00907088T patent/ES2222892T3/es not_active Expired - Lifetime
- 2000-01-31 AT AT00907088T patent/ATE267775T1/de not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP2002535237A (ja) | 2002-10-22 |
| AU758560B2 (en) | 2003-03-27 |
| EP1149057A1 (en) | 2001-10-31 |
| WO2000044682A9 (en) | 2001-08-30 |
| DE60011045D1 (de) | 2004-07-01 |
| WO2000044682A1 (en) | 2000-08-03 |
| ATE267775T1 (de) | 2004-06-15 |
| CA2361573C (en) | 2010-05-25 |
| EP1149057B1 (en) | 2004-05-26 |
| ES2222892T3 (es) | 2005-02-16 |
| JP4397531B2 (ja) | 2010-01-13 |
| CA2361573A1 (en) | 2000-08-03 |
| AU2864700A (en) | 2000-08-18 |
| US6379648B1 (en) | 2002-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60011045T2 (de) | Biolgisch abbaubare glaszusammensetzungen und deren verwendung zur herstellung eines medikaments für strahlungstherapie | |
| EP0201601B1 (en) | Glass microspheres | |
| US4889707A (en) | Composition and method for radiation synovectomy of arthritic joints | |
| US5011797A (en) | Composition and method for radiation synovectomy of arthritic joints | |
| DE69233433T2 (de) | Schichtförmige gemischte metallhydroxide zur stabilisierung von radioaktiven kolloiden | |
| Sledge et al. | Experimental radiation synovectomy by 165Dy ferric hydroxide macroaggregate | |
| HK1257437A1 (en) | Composition apparatus and method for use in pet imaging | |
| US20120070371A1 (en) | Low-Density Magnesium-Aluminum-Silicate (MAS) Microparticles for Radiotherapy and/or Radioimaging | |
| DE1514223B2 (de) | Radioaktive strahlungsquelle und verfahren zu ihrer her stellung | |
| US5061476A (en) | Radiolabeled colloid compositions and method for preparing same | |
| Silk et al. | Revised estimates of dose from ores and mineral sands | |
| DE2011612C3 (de) | Radionuklide enthaltende, resorbierbare Fäden und Filme | |
| Day et al. | Glass microspheres | |
| Hassan et al. | The impact of alpha particles on physiology of human body | |
| White | Rare earth-lithium-borate glasses for use as degradable radiopharmaceuticals | |
| Day et al. | Microspheres for Radiation Therapy | |
| Jenkins | Autoradiographic and Dosimetric Applications of the (neutron, Alpha) Reaction of LITHIUM-6 as Measured by Track Registration in Cellulose Nitrate. | |
| Burkart | On the hazards of C-14, H-3 and I-125 incorporated into the genetic matter of the cell nucleus: effects of recoil, transmutation and Auger-electrons as compared with the effects of the beta-and gamma-radiation | |
| Herrick | The Grinding of Thorium Bearing Gas Tungsten Arc Welding (GTAW) Electrodes, and their Radiological Effects in Humans | |
| DE2445264A1 (de) | Verfahren zum nachweis von glassplittern | |
| HK1131462B (en) | Composition apparatus and method for use in imaging | |
| HK1131462A (en) | Composition apparatus and method for use in imaging |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |